Felice Verduyn-van Weegen is a Partner in the EQT Life Sciences team. Felice worked for LSP from 2015 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. Next to Agomab, Felice is on several company boards for EQT life sciences, including Amolyt pharma and Evommune. Prior to joining LSP, Felice
Angelika is a purpose driven physician scientist with over 20 years of drug development expertise at Novartis, Gilead, Genentech and Amgen currently serving as the Development Unit Head of Immunology at Novartis. She earned her MD/PhD from the University of Freiburg, Germany, conduced her postdoctoral research at The Scripps Research Institute in La Jolla and
Ohad is a Partner at Pontifax, where he is focused on scouting and project evaluation. He also serves on the board of several of Pontifax’s portfolio companies including AgomAb, Step Pharma and Adcendo. Ohad obtained his MSc in Biology from Tel-Aviv University.
Ming Fang is a Managing Director at Redmile Group, LLC, a healthcare-focused investment firm. Prior to joining Redmile in 2016, Ming worked in the healthcare space as an investor at Safeguard Scientifics, a consultant at McKinsey & Company and ZS Associates, and an operator at Gilead Sciences. He received a B.A. in Computer Science from
In addition to Agomab, John is the chair of the board of Adcendo (DK), CatalYm (DE), Solid Therapeutics (DK), and Synklino (DK), as well as a non-executive director of Neophore and Storm (both UK). Prior, he was the CEO of F-star Therapeutics in Cambridge, UK (2012-18), VP Research at ImClone Systems, New York (2010-12), and
Tim is CEO and member of the Board of Directors of Agomab Therapeutics, a Belgian biotech company focusing on growth factor biology and developing therapeutics for fibrotic indications. Together with the team, he has raised $240 million and developed a broad pipeline since joining Agomab in 2019. Prior to Agomab, Tim held the position of